Atossa Therapeutics, Inc. (ATOS)Healthcare | Biotechnology | Seattle, United States | NasdaqCM
2.58 USD
-0.06
(-2.273%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.72 +0.14 (5.415%) ⇧ (Aug. 28, 2026, 7:38 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 6:08 a.m. EDT
The investment case here is broken by a deteriorating business and a hostile capital structure. Fundamentally, the company is posting massive losses, burning cash, and has just flagged a 'going concern' risk, meaning the board believes the company might not survive the next year without raising more money. The stock has lost over 98% of its value over the last nine years, and despite a recent uptick, the long-term trajectory remains a structural decline. The balance sheet is fragile, evidenced by the recent registered direct offerings where the company sold shares to raise cash, which dilutes existing shareholders and signals distress. There is no dividend to provide a floor. Technically, the stock is trading well below its 200-day average, confirming the long-term downtrend. While the short-term rating isn't a hard 'sell' (0) because the price has recently stabilized slightly above the 50-day moving average, the momentum is weak and the path of least resistance remains down. The options market confirms this pessimism, with traders loading up on puts and avoiding calls. This is a speculative biotech stock in survival mode, not a viable investment vehicle. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.667058 |
| AutoETS | 0.669812 |
| AutoTheta | 0.670377 |
| MSTL | 0.681708 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 1.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.32 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 25,746,588 |
| Forward P/E | -0.59 |
| Beta | 1.25 |
| Website | https://www.atossatherapeutics.com |
As of Aug. 22, 2026, 6:08 a.m. EDT: Speculators are positioning for a continued grind lower rather than a rebound. Put open interest significantly outweighs call open interest across all expirations, with heavy concentration in strikes below the current price ($1.00 and $2.00). While there is some call volume at higher strikes ($4.00-$9.00), the overwhelming majority of open interest sits in the money for put buyers, indicating a bearish bias where traders are betting on further downside or seeking protection against a collapse.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7714286 |
| Address1 | 448 NW Market Street |
| Address2 | Suite 500 |
| All Time High | 33,480.0 |
| All Time Low | 1.7 |
| Ask | 3.21 |
| Ask Size | 2 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 66,150 |
| Average Daily Volume3 Month | 157,204 |
| Average Volume | 157,204 |
| Average Volume10Days | 66,150 |
| Beta | 1.246 |
| Bid | 1.88 |
| Bid Size | 2 |
| Book Value | 2.689 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.58 |
| Current Ratio | 5.689 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.62 |
| Day Low | 2.5 |
| Display Name | Atossa Therapeutics |
| Dividend Date | 1,524,182,400 |
| Earnings Call Timestamp End | 1,742,905,800 |
| Earnings Call Timestamp Start | 1,742,905,800 |
| Earnings Timestamp End | 1,755,261,000 |
| Earnings Timestamp Start | 1,754,915,400 |
| Ebitda | -39,235,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.009 |
| Enterprise Value | -347,411 |
| Eps Current Year | -4.4 |
| Eps Forward | -4.38 |
| Eps Trailing Twelve Months | -4.34 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.3232 |
| Fifty Day Average Change | 0.25679994 |
| Fifty Day Average Change Percent | 0.110537164 |
| Fifty Two Week Change Percent | -77.14286 |
| Fifty Two Week High | 19.35 |
| Fifty Two Week High Change | -16.77 |
| Fifty Two Week High Change Percent | -0.8666667 |
| Fifty Two Week Low | 1.7 |
| Fifty Two Week Low Change | 0.8799999 |
| Fifty Two Week Low Change Percent | 0.51764697 |
| Fifty Two Week Range | 1.7 - 19.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,352,385,000,000 |
| Float Shares | 9,944,570 |
| Forward Eps | -4.38 |
| Forward P E | -0.58904105 |
| Free Cashflow | -23,330,876 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 16 |
| Fullday Change | -0.0600002 |
| Fullday Change Percent | -2.27273 |
| Fullday Price | 2.7197 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01846 |
| Held Percent Institutions | 0.17379999 |
| Implied Shares Outstanding | 9,979,298 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,769,990,400 |
| Last Split Factor | 1:15 |
| Long Business Summary | Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington. |
| Long Name | Atossa Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 25,746,588 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_100256926 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -37,709,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 26,345,346 |
| Number Of Analyst Opinions | 3 |
| Open | 2.62 |
| Operating Cashflow | -35,769,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 206 588 0256 |
| Post Market Change | 0.13970017 |
| Post Market Change Percent | 5.414736 |
| Post Market Price | 2.7197 |
| Post Market Time | 1,787,960,329 |
| Previous Close | 2.64 |
| Price Eps Current Year | -0.5863636 |
| Price Hint | 4 |
| Price To Book | 0.9594645 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.787 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.0600002 |
| Regular Market Change Percent | -2.27273 |
| Regular Market Day High | 2.62 |
| Regular Market Day Low | 2.5 |
| Regular Market Day Range | 2.5 - 2.62 |
| Regular Market Open | 2.62 |
| Regular Market Previous Close | 2.64 |
| Regular Market Price | 2.58 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 47,949 |
| Return On Assets | -0.50688 |
| Return On Equity | -0.89225996 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 9,979,298 |
| Shares Percent Shares Out | 0.0797 |
| Shares Short | 795,457 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 776,246 |
| Short Name | Atossa Therapeutics, Inc. |
| Short Percent Of Float | 0.0798 |
| Short Ratio | 12.76 |
| Source Interval | 15 |
| State | WA |
| Symbol | ATOS |
| Target High Price | 24.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 18.66667 |
| Target Median Price | 22.0 |
| Total Cash | 26,094,000 |
| Total Cash Per Share | 2.615 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.34 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.87515 |
| Two Hundred Day Average Change | -3.2951503 |
| Two Hundred Day Average Change Percent | -0.5608623 |
| Type Disp | Equity |
| Volume | 47,949 |
| Website | https://www.atossatherapeutics.com |
| Zip | 98,107 |